Kymera Therapeutics Accelerates KT-621 Atopic Dermatitis Trial Data to Year-End 2026 After Early Phase 2b Enrollment Completion
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (2.0× avg).
Summary
Kymera Therapeutics has completed enrollment in its Phase 2b BROADEN2 trial for KT-621 in moderate to severe atopic dermatitis, nearly six months ahead of schedule. This acceleration allows the company to bring forward the topline data readout to year-end 2026, significantly earlier than the previous mid-2027 guidance. This is a positive development for Kymera's lead immunology drug, following its Fast Track designation in April and positive Phase 1 data in June. The earlier data readout brings forward a key catalyst for the company, with Phase 3 trials now planned to initiate by mid-2027.
At the time of this announcement, KYMR was trading at $99.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $36.65 to $105.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.